Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.
18 Years
35 Years
Female
Genomic Human Endometrial Expression Profile
Trial Information
Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.
We analyze the genomic profile of egg donors in different endometrial priming protocols,
compared with natural cycle, including the conventional single long acting GnRH agonist
injection in the mid luteal phase of the previous cycle of the endometrial priming and the
single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular
phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing
hormone
- 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.
Inclusion Criteria:
- 6 egg healthy volunteer egg donors.
- Volunteers.
- 18-35 years old
- Healthy.
- BMI <28.
Exclusion Criteria:
- - BMI > 28
- Smokers-
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Outcome Measure:
genetic endometrial human profile expression
Outcome Description:
implantation related genes profile expression
Outcome Time Frame:
Oocyte donors will be followed up for four to six months
Safety Issue:
Yes
Principal Investigator
Carmen Vidal, MDphD
Investigator Role:
Principal Investigator
Investigator Affiliation:
IVI Valencia
Authority:
Spain: Spanish Agency of Medicines
Study ID:
VLC18012013
NCT ID:
NCT01778452
Start Date:
November 2009
Completion Date:
January 2013
Related Keywords:
- Genomic Human Endometrial Expression Profile
- Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.
- Adenoma
Name | Location |
|---|
